Jamie N. Connarn

3.1k total citations
22 papers, 522 citations indexed

About

Jamie N. Connarn is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Jamie N. Connarn has authored 22 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Jamie N. Connarn's work include CAR-T cell therapy research (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jamie N. Connarn is often cited by papers focused on CAR-T cell therapy research (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jamie N. Connarn collaborates with scholars based in United States, Switzerland and Germany. Jamie N. Connarn's co-authors include Duxin Sun, Erik R. P. Zuiderweg, Jason E. Gestwicki, Zapporah T. Young, Atta Ahmad, Sharan R. Srinivasan, Xiaokai Li, Andrew Babiskin, Xinyuan Zhang and Joseph Burnett and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Jamie N. Connarn

21 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jamie N. Connarn United States	11	304	186	68	51	49	22	522
Ayşe Latif United Kingdom	14	227 0.7×	153 0.8×	44 0.6×	20 0.4×	40 0.8×	26	645
Philippe Genne France	15	368 1.2×	262 1.4×	29 0.4×	29 0.6×	66 1.3×	30	632
King Leung Fung United States	10	204 0.7×	349 1.9×	34 0.5×	53 1.0×	14 0.3×	13	608
Kristen M. John United States	3	329 1.1×	136 0.7×	17 0.3×	33 0.6×	53 1.1×	5	745
Ray Liu United States	10	226 0.7×	153 0.8×	25 0.4×	33 0.6×	36 0.7×	18	407
Virginie Moucadel France	17	422 1.4×	194 1.0×	81 1.2×	22 0.4×	114 2.3×	26	934
Beverly A. Teicher United States	15	387 1.3×	240 1.3×	42 0.6×	57 1.1×	25 0.5×	32	665
Linda R. Barone United States	9	298 1.0×	242 1.3×	34 0.5×	55 1.1×	33 0.7×	12	639
Janet S. Macpherson United Kingdom	16	385 1.3×	333 1.8×	22 0.3×	30 0.6×	69 1.4×	30	861
Margaux Fresnais Germany	13	304 1.0×	137 0.7×	26 0.4×	22 0.4×	44 0.9×	26	597

Countries citing papers authored by Jamie N. Connarn

Since Specialization

Citations

This map shows the geographic impact of Jamie N. Connarn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie N. Connarn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie N. Connarn more than expected).

Fields of papers citing papers by Jamie N. Connarn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie N. Connarn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie N. Connarn. The network helps show where Jamie N. Connarn may publish in the future.

Co-authorship network of co-authors of Jamie N. Connarn

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie N. Connarn. A scholar is included among the top collaborators of Jamie N. Connarn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie N. Connarn. Jamie N. Connarn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Connarn, Jamie N., et al.. (2024). A novel Bayesian generative approach for estimating tumor dynamics from published studies. CPT Pharmacometrics & Systems Pharmacology. 13(8). 1341–1353. 1 indexed citations

Kelly, William Kevin, Leonard J. Appleman, C-C. Lin, et al.. (2024). 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study. Annals of Oncology. 35. S963–S964. 1 indexed citations

Connarn, Jamie N., Han Witjes, Rik de Greef, et al.. (2023). Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1687–1697. 6 indexed citations

Burton, Jackson, Bilal Abuasal, Jamie N. Connarn, et al.. (2023). Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision. Clinical Pharmacology & Therapeutics. 114(3). 507–510.

Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S1576–S1576. 1 indexed citations

Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S953–S954. 8 indexed citations

Adams, Mary Beth, Anastasia Parton, Jamie N. Connarn, et al.. (2022). CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production. Arthritis Research & Therapy. 24(1). 199–199. 17 indexed citations

Munshi, Nikhil C., Larry D. Anderson, Nina Shah, et al.. (2020). Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. Journal of Clinical Oncology. 38(15_suppl). 8503–8503. 96 indexed citations

Li, Yan, Jamie N. Connarn, Jian Chen, et al.. (2019). <p>Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment</p>. Clinical Pharmacology Advances and Applications. Volume 11. 39–50. 7 indexed citations

10.

Coyne, Daniel W., William T. Smith, Jamie N. Connarn, et al.. (2019). Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney International Reports. 4(11). 1585–1597. 23 indexed citations

11.

Gordon, Michael S., Geoffrey I. Shapiro, John Sarantopoulos, et al.. (2018). A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).. Journal of Clinical Oncology. 36(15_suppl). 2547–2547. 6 indexed citations

12.

Connarn, Jamie N., Stephanie A. Flowers, Marisa Kelly, et al.. (2017). Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. The AAPS Journal. 19(5). 1513–1522. 23 indexed citations

13.

Connarn, Jamie N., et al.. (2017). Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies. Clinical Pharmacology in Drug Development. 7(5). 465–473. 9 indexed citations

14.

Sun, Lichao, Joseph Burnett, Fangying Xu, et al.. (2016). Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. Oncotarget. 7(32). 51408–51422. 39 indexed citations

15.

Burnett, Joseph, Hasan Körkaya, Maria Ouzounova, et al.. (2015). Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options. Scientific Reports. 5(1). 15821–15821. 54 indexed citations

16.

Connarn, Jamie N., Xinyuan Zhang, Andrew Babiskin, & Duxin Sun. (2015). Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine. Drug Metabolism and Disposition. 43(7). 1019–1027. 36 indexed citations

17.

Burnett, Joseph, Hasan Körkaya, Hui Jiang, et al.. (2014). Abstract 218: MEOX-1 as a novel cancer stem cell target for treatment of trastuzumab-resistant Her2+ breast cancers. Cancer Research. 74(19_Supplement). 218–218. 2 indexed citations

18.

Connarn, Jamie N., Victoria A. Assimon, Rebecca A. Reed, et al.. (2013). The Molecular Chaperone Hsp70 Activates Protein Phosphatase 5 (PP5) by Binding the Tetratricopeptide Repeat (TPR) Domain. Journal of Biological Chemistry. 289(5). 2908–2917. 36 indexed citations

19.

Li, Xiaokai, Sharan R. Srinivasan, Jamie N. Connarn, et al.. (2013). Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents. ACS Medicinal Chemistry Letters. 4(11). 1042–1047. 123 indexed citations

20.

Chen, Hongwei, Peng Zou, Jamie N. Connarn, Hayley J. Paholak, & Duxin Sun. (2012). Intracellular dissociation of a polymer coating from nanoparticles. Nano Research. 5(11). 815–825. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact